In the open-label phase IIa segment ( N = @ ) , the majority of the @ AEs reported in @ ( @ % ) balugrastim-treated patients were grade @ ( @ % ) , with @ % grade @ , @ % grade @ ( one AE of vomiting ) , and none grade @ .